Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Clinical trial NCT06082102 · RECRUITING
Trial details
- NCT number
- NCT06082102
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-19
- Primary completion
- 2028-08-31
- Enrollment
- 324
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.